Lars Holtug - 18 Mar 2026 Form 3 Insider Report for Ascendis Pharma A/S (ASND)

Role
Director
Signature
/s/ Michael Wolff Jensen as attorney-in-fact for Lars Holtug
Issuer symbol
ASND
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 18:10:13 UTC

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
HOLTUG LARS Director C/O ASCENDIS PHARMA A/S, TUBORG BOULEVARD 12, HELLERUP, DENMARK /s/ Michael Wolff Jensen as attorney-in-fact for Lars Holtug 18 Mar 2026 0001965626

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ASND Ordinary Shares 4,236 18 Mar 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ASND Warrants 18 Mar 2026 Ordinary Shares 35,000 $61.00 Direct F2
holding ASND Warrants 18 Mar 2026 Ordinary Shares 7,500 $108.00 Direct F2
holding ASND Warrants 18 Mar 2026 Ordinary Shares 6,420 $176.28 Direct F2
holding ASND Warrants 18 Mar 2026 Ordinary Shares 3,053 $139.65 Direct F2
holding ASND Restricted Stock Units 18 Mar 2026 Ordinary Shares 1,374 Direct F3, F4
holding ASND Restricted Stock Units 18 Mar 2026 Ordinary Shares 2,070 Direct F4, F5
holding ASND Restricted Stock Units 18 Mar 2026 Ordinary Shares 1,930 Direct F4, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share.
F2 The warrants are fully vested and currently exercisable.
F3 The restricted stock units vest on March 1, 2027 and have no expiration date.
F4 Each restricted stock unit represents a contingent right to receive one ADS.
F5 The restricted stock units vest in two equal annual installments beginning on March 1, 2027.
F6 The restricted stock units vest in three equal annual installments beginning on March 1, 2027.